Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat. Issue 1 (2nd January 2018)

• Record Type: Journal Article
• Authors: Gautam, Ashish; Zhu, Yanyan; Ma, Esprit; Lee, Shih-Yuan; Zagadailov, Erin; Teasell, Jeremy; Richhariya, Akshara; Bonthapally, Vijayveer; Huebner, Dirk
• Is Part Of: Leukemia & lymphoma. Volume 59:Issue 1(2018)
• Page Start: 69
• Page End: 76
• Publication Date: 2018-01-02
• Subjects: Brentuximab vedotin -- CD30 -- hematopoietic stem cell transplantation -- Hodgkin lymphoma -- numbers needed to treat; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2017.1324160
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The number needed to treat (NNT) with brentuximab vedotin consolidation therapy post-autologous stem cell transplant (ASCT) versus placebo in the phase 3 AETHERA trial to avoid one additional event of disease progression/death was evaluated. AETHERA included 329 Hodgkin lymphoma patients at increased risk of progression post-ASCT who received brentuximab vedotin 1.8 mg/kg ( n = 165) or placebo ( n = 164) on day 1 of each 21-d cycle (up to 16 cycles). Over 60 months, the NNT with brentuximab vedotin ranged from 4.08 to 7.79 for the intent-to-treat population, 3.18–6.07 for patients with ≥2 risk factors, and 2.98–5.65 for patients with ≥3 risk factors. At various time points, and dependent on the risk group, 3–8 patients would need to be treated with brentuximab vedotin consolidation therapy to prevent a disease progression/death, compared with placebo. Patients with increased risk of relapse may benefit most from brentuximab vedotin.